Arjo’s interim report January-June 2026

Arjo reported Q2 net sales of SEK 2,759M (vs. SEK 2,678M), up 4.7% organically on high demand. Profitability improved at the operating level (adjusted operating profit SEK 211M vs. SEK 208M; adjusted EBITDA SEK 482M vs. SEK 475M), but gross margin declined to 42.1% from 43.4% (-130bps). Management highlighted steps to improve focus, efficiency, and profitability to support long-term value creation.

Analysis

The important read-through is not the modest revenue beat; it is that growth came with gross-margin leakage while EBITDA barely moved. That usually signals volume-led improvement, not durable pricing power, and it caps the near-term earnings multiple unless management can prove the mix/cost profile is improving. In med-tech equipment, the market tends to reward margin inflection more than low-single-digit top-line growth, so the stock can look optically cheap but still be a value trap if gross margin stays under pressure.

The “focus and efficiency” language suggests a portfolio clean-up or restructuring path that can help over 2-4 quarters, but those benefits often arrive after one-time costs and execution risk. In the meantime, competitors with better scale and cleaner service mix can take share in the higher-margin portions of the market, while more price-sensitive rivals may be forced into discounting. If Arjo is pruning lower-quality revenue, the upside is better ROIC and a cleaner story in 6-18 months; if not, the market may start treating this as a low-quality growth business.

Contrarian view: consensus may be too quick to extrapolate the organic growth rate and too slow to discount the margin compression. The falsifier is straightforward: if next quarter gross margin reclaims the low-43s and EBITDA margin expands, the de-rating risk eases; if gross margin slips another 50-100 bps, the market will likely focus on earnings durability rather than sales growth. For now, the better setup is likely relative value rather than outright beta exposure.

Key Decisions for Investors

• Do not chase the print outright; wait 1 quarter for confirmation that gross margin stabilizes before adding long exposure to Arjo.
• If you own European med-tech broadly, consider a relative-value rotation: long higher-quality diversified healthcare equipment names, short Arjo, until margin recovery is visible.
• Set an alert on Arjo gross margin at 42% and 41.5%: above 42.5% is constructive for a 3-6 month re-rating; below 41.5% argues for de-risking.
• For investors needing exposure, use a staggered entry over 4-8 weeks rather than buying the first bounce; the catalyst path is likely gradual, not immediate.
• Watch the next guidance update for evidence that efficiency actions are converting into EBITDA margin expansion; without that, treat this as a hold, not a conviction long.